WCLC 2016 | The future of drug development: broader signatures in precision medicine, beyond genomics

Yu Shyr

Yu Shyr, PhD of Vanderbilt University School of Medicine, Nashville, TN discusses drug development in lung cancer and a need for a broader approach, using genomics, proteomics, and lipidomics to create a signature or network in personalized precision medicine. Currently, most drug development focuses on targeted therapy for single gene mutations with low prevalence rates. There is an obvious lack of focus on those patients without these mutations. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter